Semaglutide and Water: Hydration, Mixing Questions and What the Evidence Says

What STEP 1 and the licensed SmPC tell us about fluid intake on semaglutide

The STEP 1 trial (68 weeks, published in the New England Journal of Medicine, roughly 1,900 adults with obesity or overweight and a weight-related condition) established semaglutide 2.4 mg as an effective once-weekly injection, with an average body-weight reduction of around 15% over the study period. The most commonly reported side effects across STEP 1 were gastrointestinal: nausea, diarrhoea, vomiting and constipation. These effects tend to cluster in the early weeks of treatment or after each dose increase, and they matter for hydration because they can quietly reduce how much you drink.

The NHS semaglutide medicines page notes that if vomiting or diarrhoea is severe, there is a real risk of dehydration and kidney strain, and advises seeking medical help if symptoms persist or worsen. That's not a theoretical concern, it's the reason keeping fluid intake steady is part of sensible day-to-day management on this treatment. Plain water, diluted squash, clear broths: anything that keeps you hydrated helps. Coffee and alcohol don't count; both can make nausea worse, especially in the early weeks.

There is no trial-based "target" volume for daily fluid intake specific to semaglutide. General NHS guidance on healthy fluid intake (roughly six to eight glasses of water or other fluids daily) is a reasonable starting point, but your own prescriber can give you more tailored advice if you are struggling with GI symptoms. The key point from the evidence is that hydration is an active consideration on this treatment, not an afterthought.

Licensed Wegovy pens do not need mixing: where the "semaglutide water" confusion comes from

The question about mixing semaglutide with water comes from a specific practice that became widespread in the US and has crossed into UK search traffic: compounded semaglutide, sometimes sold as a powder or lyophilised pellet, which buyers are instructed to reconstitute with bacteriostatic water before injecting. This is not how any licensed UK semaglutide product works.

Licensed Wegovy pens (the subcutaneous injection) are pre-filled by Novo Nordisk and come ready to use straight from the fridge. There is no powder, no vial, no water to draw up. If someone is describing a process that involves mixing semaglutide with water before injecting, they are not describing a licensed UK product. The MHRA has warned publicly about illegally traded and counterfeit weight-loss medicines; fake pens have been found to contain incorrect substances, and dosing errors with reconstituted compounds can be dangerous. You can report suspect sellers at the MHRA's Yellow Card site.

If you have questions about what a legitimate Wegovy pen looks like, how it is stored or how it is used, the Patient Information Leaflet supplied with your pen is the authoritative reference, or ask your prescriber. Worth knowing: when your pen arrives through a GPhC-registered pharmacy like ours, it is shipped refrigerated in plain, unbranded packaging via DPD tracked delivery, so you can confirm it has been handled correctly the whole way.

The oral Wegovy tablet: the one time water genuinely is part of the dosing process

On 11 June 2026, the MHRA approved oral semaglutide (Wegovy tablets) as the first licensed oral GLP-1 medicine for weight management in the UK. The tablet does involve a specific and important relationship with water, but it is tightly defined, and it is not about reconstitution.

The tablet must be taken first thing in the morning on an empty stomach, swallowed whole with no more than around 120 ml of plain water. That specific small volume matters: too much water can reduce absorption of the medicine through its co-formulated absorption enhancer. After taking the tablet, you wait at least 30 minutes before eating, drinking anything else (including tea or coffee) or taking other oral medicines. The dose escalates from 1.5 mg through 4 mg and 9 mg to the 25 mg maintenance dose, with at least a month at each level.

One practical advantage: unlike the injection pen, the tablet requires no refrigeration. It is a room-temperature medicine, which simplifies travel. If you are curious how this compares to the injection in terms of results or practical routine, our Wegovy overview covers both formulations. Questions about cost are addressed on our Wegovy cost context page, which explains what a legitimate private price actually includes.

Water retention and weight changes on semaglutide

Some people notice changes in fluid retention when they start semaglutide, either a drop in water weight early on, or occasionally some bloating. This is a separate topic from hydration, and it intersects with how the scales behave in the first few weeks of treatment. Wegovy and water weight is covered in more detail elsewhere, but the short version is: early weight changes on any GLP-1 treatment often include a fluid component alongside fat loss, and this can make week-to-week scale readings hard to interpret.

The evidence base for semaglutide focuses on sustained fat-mass reduction over many months, not on short-term water-weight shifts. STEP 1's 15% average weight reduction at 68 weeks reflects genuine, meaningful change, but it doesn't happen in a straight line. Expecting a steady drop and finding a plateau in week three is normal, and often related to fluid fluctuations rather than the medicine not working.

If you would like to explore treatment options or discuss whether semaglutide is clinically appropriate for you, our clinical team (including our lead prescriber) reviews every consultation personally. You can also read about the full range of weight-loss treatments we support, or go straight to start your free consultation.